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Lung cancer remains the leading cause of cancer
death. Genome sequencing of lung tumors from pa-
tients with squamous cell carcinoma has identified
SMAD4 to be frequently mutated. Here, we use a
mouse model to determine the molecular mecha-
nisms by which Smad4 loss leads to lung cancer pro-
gression. Mice with ablation of Pten and Smad4 in
airway epithelium develop metastatic adenosqua-
mous tumors.Comparative transcriptomicand invivo
cistromic analyses determine that loss of PTEN and
SMAD4 results in ELF3 and ErbB2 pathway activation
due to decreased expression of ERRFI1, a negative
regulator of ERBB2 in mouse and human cells. The
combinatorial inhibition of ErbB2 and Akt signaling
attenuate tumor progression and cell invasion,
respectively. Expression profile analysis of human
lung tumors substantiated the importance of the
ErbB2/Akt/ELF3 signaling pathway as both a prog-
nostic biomarker and a therapeutic drug target for
treating lung cancer.
INTRODUCTION
The dichotomous division of primary lung cancer into non-small
cell lung carcinoma (NSCLC) and small cell lung carcinoma
(SCLC) is based on histological appearance and clinical char-
acteristics (Shames and Wistuba, 2014). NSCLC is the pre-
dominant type of primary lung cancer and is subdivided into
adenocarcinoma (AD), squamous cell carcinoma (SCC), and
large cell carcinoma (LCC), although, in over 50% of the cases,
a mixed histological phenotype is detected, indicating a contin-
uum of heterogeneity in lung cancer (Jemal et al., 2010; Walker,
2008). Despite the histological differences, the 5-year survival
rate for all early-stage NSCLC lung cancers is estimated to beCellabout 50%, but it is significantly reduced, to less than 5, in can-
cers that are diagnosed with distant metastasis (Howlader et al.,
2014). Given the disproportionate number of lung cancer pa-
tients that present with distant metastasis or at a late disease
stage (Howlader et al., 2014), lung cancer remains the leading
cause of cancer-related death (Siegel et al., 2014). Therefore,
there is an urgent need to identify biomarkers and drug targets
for early diagnosis and treatment of human lung cancer.
Lung cancer initiation and progression is driven by the
stepwise accumulation of genetic alterations (Sakashita et al.,
2014), including inactivation of tumor suppressor genes, such
as PTEN, p53, and SMAD4 (Cancer Genome Atlas Research
Network, 2012), and mutation and/or amplification of oncogenic
genes, such as Kras, EGFR, and ERBB2 that control cell prolifer-
ation (Cancer Genome Atlas Research Network, 2014). In partic-
ular, PTEN, a suppressor of the PI3K/Akt signaling pathway, is
highly dysregulated (Cancer Genome Atlas Research Network,
2012) and is recognized as a prognostic marker in human lung
cancer (Yanagawa et al., 2012). However, deletion of Pten in
airway epithelial cells and its biological function in animal models
of lung cancer has produced inconsistent results. While deletion
of Pten in the airway epithelial cells using the Cre recombinase
under the Club Cell Secretory Protein promoter (CCSPCre) re-
sulted in no discernible effect on bronchial epithelial cell mor-
phology in mice (Li et al., 2008; Iwanaga et al., 2008), deletion
of Pten in the distal airways and alveolar cells resulted in hyper-
plasia and lung AD in mice (Perl et al., 2002; Dave´ et al., 2008;
Yanagi et al., 2007). Recently, Pten deletion alone in airway basal
cells was shown to initiate lung tumor formation, but with low
incidence and long latency (Malkoski et al., 2014), and inactiva-
tion of Lkb1 and Pten using an Ad-Cre inhalation system resulted
in development of lung cancer that closely resemble human lung
SCC (Xu et al., 2014). Given these contradictory results, we ex-
pressed a codon optimized Cre recombinase under the control
of the CCSP promoter (CCSPicre) to examine the role of Pten in
lung cancer development.
In this report, we show that mice with efficient expression
of Cre in their proximal airways (CCSPicre) crossed with floxedReports 10, 1599–1613, March 10, 2015 ª2015 The Authors 1599
Figure 1. Deletion of Pten in Mouse Bronchial Epithelial Cells Results in Hyperplasia and Alters TGF-b Signaling
(A) Representative whole-mount X-gal staining of mouse lungs in different stages. The blue X-gal staining showed CCSPiCre expressed in tracheal and bronchial
airway epithelial cells in R26R (left) and CCSPiCre/R26R (right) mice (upper panel). The white arrows indicate the blue staining of X-gal in tracheal and bronchial
airway epithelial cells and the black arrows indicate the staining of X-gal in the alveolar type II cells; trachea (TR), bronchi (BI), and bronchiole (BE).
(B) IHC staining of PTEN in lungs of 7-month-old WT and Ptend/d mice. PTEN staining is strongly present in the epithelium (brown staining) of WT mice and not in
the epithelial cells of the Ptend/d mouse lung.
(C) WB analysis of PTEN and AKT expression and Akt phosphorylation (p-AKT) in lungs of 7-month-old mice. Increased p-AKT was observed in Ptend/d mouse
lungs.
(D) The heatmap for the 1,847 differentially regulated genes (2,324 probes) in the microarray analysis of lungs from 7-month-old Ptend/d mice (n = 6) when
compared to 7-month-old WT mice (n = 6).
(E) IPA of gene microarray data revealed top changed upstream regulators in Ptend/d mice, as compared to WT mice.
(legend continued on next page)
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Pten allele mice develop airway epithelial hyperplasia without
progression to tumor. In an attempt to identify the mechanism
responsible for the failure of hyperplastic epithelial cells lacking
Pten to progress to lung tumors, we discovered alterations in
transforming growth factor b (TGF-b)-SMAD4 signaling axis in
the hyperplastic airway epithelial cells lacking Pten. Concurrent
ablation of Smad4 and Pten in the airways of mice resulted in
the spontaneous development of proximal airway tumors with
metastasis to distal organs. Transcriptomic and in vivo cistromic
analyses of lung tumors demonstrated that ablation ofSmad4 re-
sulted in the activation of the ErbB2 signaling pathway. We then
demonstrate that the activation of ErbB2 signaling is due to alter-
ation in the expression of Errfi1 (ERBBReceptor Feedback Inhib-
itor 1), a negative regulator of ErbB2 activation and direct target
of SMAD4 transcriptional regulation. Furthermore, we identified
Elf3 as an essential target of the signaling pathways that control
lung tumor cell proliferation and invasion. SMAD4 directly in-
hibits and ErbB2 signaling induces the expression and activity
of Elf3. Thus, the ERRFI1/ErbB2/ELF3 signaling axis may be tar-
geted for the treatment of lung tumors that have an attenuated
expression of PTEN and SMAD4.
RESULTS
Deletion of Pten in Mouse Bronchial Epithelial Cells
Results in Hyperplasia and Alters TGF-b Signaling
Our previous study showed that CCSPCre-mediated lung-spe-
cific deletion of Pten in bronchial epithelial cells had no discern-
ible phenotype unless combined with Kras activation (Iwanaga
et al., 2008). The lack of histological change in the airway epithe-
lial cell in mice with deletion of Ptenmay have been in part due to
the low efficiency of Cre-induced recombination. To address
this possibility, we generated a mouse line that expresses an
improved Cre (iCre) (Shimshek et al., 2002) inserted into the
CCSP locus (CCSPiCre model) (Figure S1A). The Rosa 26 reporter
mice crossed with CCSPiCre showed efficient recombination in
epithelial cells lining the trachea, bronchi, and distal airways
with some recombination in alveolar type II cells (Figure 1A).
The recombination efficiency of CCSPiCre was higher than that
of CCSPCre, as demonstrated by the increased X-gal staining
of the lung (Figure 1A) (Li et al., 2008; Soriano, 1999). The recom-
bination observed inmice expressingCCSPiCre is confined to the
lungs with no recombination observed in other tissues examined
(Figure S1B). Mice with the floxed Pten allele (Ptenf/f) (Lesche
et al., 2002) were crossed with CCSPicre mice to achieve
airway-specific deletion of Pten (Ptend/d). Immunohistochemical
(IHC) staining for PTEN showed loss of the PTEN protein in the
airway epithelium of Ptend/d mice with prominent hyperplasia
at 9 months of age (Figure 1B). Western blot (WB) analysis of
lung extract showed a significant reduction of PTEN protein
and the expected increase in the p-AKT level (Figure 1C). Inter-
estingly, even at 15 months of age hyperplasia did not progress
to carcinoma indicating that in the absence of Pten other tumor(F) WB analysis of SMAD4 protein expression in 7-month-old mouse lungs.
(G) IHC staining of SMAD4 (brown staining) in 7-month-old WT and Ptend/d mou
(H) Kaplan-Meier plot of probability of recurrence-free survival based on the cyto
tissue array data set.
Cellsuppressor genes may be altered and prevent lung tumor
development.
To identify which genes are significantly altered in the absence
of Pten, microarray analysis comparing lung RNAs isolated from
control and Ptend/d mice was performed and identified 1,847
unique genes that were significantly altered when Pten was ab-
lated (Figure 1D). Ingenuity knowledge-based analysis (IPA) of
the altered genes identified TGF-b1 as one of the top upstream
regulators, indicating its potential role in preventing Ptend/d
airway epithelia progression to tumor (Figure 1E). The TGF-b
signaling pathway has been shown to be critical in many types
of cancer (de Caestecker et al., 2000), including lung cancer
(Jeon and Jen, 2010). Indeed, dramatic changes in the compo-
nents of the TGF-b/BMP pathways were observed (Figures
S1C and 1F). We validated the alteration of several genes in
the TGF-b1 pathway in the lungs from Ptend/d mice (Table S1;
Figure S1D) and focused on SMAD4, a tumor suppressor gene
that is activated in response to TGF-b signaling (Shi et al.,
1997) and has been recently found to be one of the highly
mutated genes in human lung SCC (Cancer Genome Atlas
Research Network, 2012). IHC and WB analyses of lung tissues
showed a significant increase in expression of SMAD4 in the
lungs of Ptend/d mouse, as compared with control mice (Figures
1F and 1G), supporting a possible protective role for TGF-b
signaling in the prevention of lung tumors in Pten deficiency.
Higher Level of SMAD4 Is Associated with Improved
Overall Survival in Human Lung Cancer
The tumor suppressor function of SMAD4 has been well estab-
lished in a number of human cancers (Ding et al., 2011; Tascilar
et al., 2001; Liu, 2001; Miyaki and Kuroki, 2003; Teng et al.,
2006), but its role in lung cancer development remains less clear
(Ke et al., 2008; Nagatake et al., 1996). In line with reported
downregulated expression of SMAD4 in a subset of human pri-
mary lung tumors (Ke et al., 2008), TCGA expression analysis
from a clinical database revealed the reverse correlation of
SMAD4 copy number with tumor grades and patients’ 5-year
survival rate (Figure S1E). In addition to the bioinformatics anal-
ysis of mRNA expression, we also examined the expression of
the SMAD4 protein in 479 cases of AD and SCC lung cancer
samples using tissue microarray (Table S2). Kaplan-Meier sur-
vival analysis of the tissue microarray results revealed that pa-
tients with higher retention of cytoplasmic SMAD4 expression
showed significant improvement in recurrence-free survival
(p = 0.03, log-rank test) (Figures 1H and S1F). Taken together,
these data demonstrate that SMAD4 is a potential suppressor
for lung cancer progression.
Deletion of Smad4 in Pten-Null Background Promotes
Tumor Growth and Metastasis
To determine if increased expression of SMAD4 plays an inhibi-
tory role in lung tumor development in Ptend/d mice, we crossed
Smad4f/f mice (Yang et al., 2002) with CCSPicrePtenf/f mice tose lungs.
plasmic SMAD4 protein expression index in lung cancer patients from SMAD4
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generate mice with a double deletion of Pten and Smad4 in
the airway epithelium (Ptend/dSmad4d/d). Smad4d/d, although
showing high deletion efficiency (Figure S2A), failed to show
any discernable changes in the epithelium. Additional loss of
Smad4 in the Ptend/d mice resulted in primary lung carcinoma
in the proximal airways at 9 months of age (Figures 2A and 2B).
H&E staining examination of the lung histology revealed a high
rate of perineural invasionwith architectural distortion (Figure 2B).
Peroxidase acid Schiff (PAS) staining of the lungs identified
glycogen and mucin-rich deposits in the tumors (Figure 2B).
Furthermore, lung tumors expressed TTF1 and KRT7 biomarkers
present in human lung AD (Su et al., 2006; Dennis et al., 2005), as
well as p63, SOX2, and KRT5 markers for squamous cell lung
cancers (Xu et al., 2014), suggesting mixed features of adeno
and squamous carcinomaphenotype (Figures 2C andS2B). Dou-
ble staining of KRT5 and KRT7 or TTF1, respectively, showed no
overlapping between the markers of AD and SCC in the tumors.
This further indicates that the Ptend/dSmad4d/d mouse tumors
belong to adenosquamous cell carcinoma (Figures S2C and
S2D). Meanwhile, IHC analysis of tumors revealed positive
CCSP, but not surfactant protein C (SPC), indicating the lack of
type II cell marker expression in the malignant cell (Figure 2D).
The observedmouse tumors initiated from the proximal airway
epithelial cells where CCSPiCre showed stronger expression
compared with that of CCSPCre (Figure 1A) (Li et al., 2008). In or-
der to determine if the CCSPiCre mouse targets recombination
exclusively to the Club cells or is active in other cell types,
such as p63-expressing basal cells in upper airways, we deter-
mined the specificity of Cre activity in the upper airways. First,
we determined if there was Cre activity in basal cells of normal
lung. Double immunofluorescence in the lungs of CCSPiCre
mice crossed to the R26R Lacz reporter mice showed that there
was overlapping staining of p63 and Lacz in a subpopulation of
basal cells in the tracheal and bronchial epithelium (Figure S2E),
indicating that Cre activity was not limited to Club cells of the
lungs. Double staining of lungs with p63 and PTEN or SMAD4
in the tumors of the Ptend/dSmad4d/d mice determined if the in-
crease in p63 positive cells had loss of PTEN and SMAD4 or if
the increase in p63 was due to paracrine regulation of p63 cells
that were then interspersed throughout the tumor mass. This
analysis that lungs from Ptend/dSmad4d/d mice showed no
expression of PTEN and SMAD4 in p63 positive cells in the tu-
mors, while lungs from wild-type (WT) mice show expression of
PTEN and SMAD4 in p63-expressing cells (Figure 2E), indicating
some tumor cells might originate from transformed basal cells
expressing CCSPiCre. Meanwhile, it was determined that some
Ptend/dSmad4d/d mouse lung cells expressed neither p63 and
PTEN or SMAD4 (Figure 2E). This may be due to the transforma-
tion of Ptend/dSmad4d/dmouse tumor cells other than basal cells
or may indicate a complex lineage of cell differentiation during
tumor progression. Taken together, the adenosquamous pheno-
type observed in our mouse model may not only be the result of
transformation of differentiated Club cells, but also could be the
result of transformation of a more yet to be determined cell type,
at least including some basal cells having the CCSPiCre activity.
Over 60% of Ptend/dSmad4d/d mice developed primary lung
tumors at 9 months of age, while 100% showed primary tumors
at 12 months of age (Figure 2F). In addition to primary lung tu-1602 Cell Reports 10, 1599–1613, March 10, 2015 ª2015 The Authormors, and in keeping with highly metastatic human lung tumors,
approximately 70% and 40% of Ptend/dSmad4d/d mice at
12 months of age spontaneously developed metastasis to the
stomach and liver, respectively (Nagashima et al., 2004) (Fig-
ure 2F). Detection of TTF1 in all liver tumors and a subset of
stomach tumors indicated that they originated from the lung
(Su et al., 2006; Dennis et al., 2005) (Figure 2G). Ki67 staining
demonstrated that cell proliferation significantly increased in
Ptend/dSmad4d/d tumors when compared to the WT, Smad4d/d,
or Ptend/d mice, whereas no statistically significant changes in
apoptosis were found among the WT, Smad4d/d, Ptend/d, and
Ptend/dSmad4d/d mice, as measured by TUNEL assay (Figures
S2F and S2G). Consistent with a previous finding that Pten de-
letion induces senescence in a prostate tumor mouse model
(Ahmad et al., 2011), Ptend/d mice had high levels of senescence
in lung epithelium (Figure S2H). Importantly, the senescence
induced by Pten deletion was abolished upon Smad4 deletion
in Ptend/dSmad4d/d mice (Figure S2H).
Small interfering RNA (siRNA)-mediated knockdown of PTEN
and SMAD4 in immortalized human bronchial epithelial cell
lines BEAS-2B and NL20 was conducted to determine the role
of these regulators in human lung. Compared to controls, in-
creased cell migration and invasion was observed in cells with
knockdown of PTEN and SMAD4 (Figures S2I–S2K, S2M,
and S2N). Interestingly, while knockdown of PTEN alone in-
creased cell proliferation, migration, and invasion, knockdown
of SMAD4 alone did not significantly alter any of these cellular
activities (Figures S2L and S2O), Together, these findings
demonstrate a prominent role for SMAD4 that prevents lung can-
cer development when the expression of Pten is altered in the
airway epithelium.
Lung Tumors from Ptend/dSmad4d/d Mice Correlate
Strongly with Human Lung Cancer
In order to investigate the molecular changes in the tumors of
Ptend/dSmad4d/d, we performed comparative genomic expres-
sion profiles in lung tumors isolated from Ptend/dSmad4d/d
mice and normal lung tissue from WT mice. A total of 2,128
unique genes were differentially regulated (p < 0.01, fold change
>1.4) (Figure 3A). IPA of the differentially regulated genes identi-
fied cell movement as the top functional annotation, indicating a
role for PTEN and SMAD4 in regulating cell migration and inva-
sionPtend/dSmad4d/dmice (Figure 3B).We also validated a num-
ber of the differentially regulated genes (e.g., Agr2, and Erbb2)
with known function in cell motility (Figure 3C; Table S3).
Comparative genomics using an expression data set of human
lung tumors with distinct histological subtypes (Takeuchi et al.,
2006) with the gene expression data set in the Ptend/dSmad4d/d
mice found the highest correlation of Ptend/dSmad4d/d murine
lung tumor gene signatures with that of the human LCNEC,
SCLC, and SCC subtypes (Figure 3D), confirming the notion
that genetic variations are common even among histologically
diverse lung tumors.
Deletion of Smad4 in Pten-Null Background Activates
the ErbB2/Akt Signaling
In order to identify the early molecular targets that drive lung tu-
mor development that are controlled bySmad4, genemicroarrays
Figure 2. Deletion of Smad4 in the Pten-Null Background Promotes Tumor Growth and Metastasis
(A) H&E staining analysis of 9-month-old mouse lungs. Boxed areas are magnified in the panels directly below.
(B) H&E and PAS staining analysis of primary lung tumors from 9-month-old Ptend/dSmad4d/d mice. Primary lung tumors are indicated by black arrows.
(C) IHC staining of WT and Ptend/dSmad4d/d mouse lung tumors for p63, SOX2, KRT5, TTF1, and EpCAM. The regions labeled by black or red dash boxes are
representative tumor epithelium magnified in adjacent panels.
(D) IHC staining of CCSP, themarker for Club cells, and of SPC, themarker for type II alveolar cells, onWT andPtend/dSmad4d/d mouse lungs. The regions labeled
by black or red dash boxes are representative tumor epithelium magnified in adjacent panels.
(E) Immunofluorescence staining of p63 and PTEN (left panel) or SMAD4 (right panel) in WT mouse lungs and Ptend/dSmad4d/d mouse tumors. Yellow
arrows indicate the cells coexpressing p63 and PTEN/SMAD4; white arrows indicate the cells only expressing p63; red arrows indicate the cells only expressing
PTEN/SMAD4; white triangles indicate the cells expressing neither p63 nor PTEN/SMAD4.
(F) Summary of Ptend/dSmad4d/d mice with frequency of lung tumor and metastases as it relates to age.
(G)Metastases in the stomach and liver from primary lung tumors. TTF1, amarker for the diagnosis of metastatic tumor from the lung, was positive in the stomach
and liver.
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Figure 3. Lung Tumor from Ptend/dSmad4d/d Mice Correlates Strongly with Human Lung Cancers
(A) The heatmap for the 2,128 differentially regulated genes (2,709 probes) in the microarray analysis of lung tumors from 12-month-old Ptend/dSmad4d/d mice
(n = 3) when compared to lungs from 12-month-old WT mice (n = 3).
(B) Top molecular and cellular functions identified by IPA of the gene microarray data from lung tumors of Ptend/dSmad4d/d mice, in comparison with that of
WT mouse lungs.
(C) Quantitative real-time PCR analysis of some of these significantly altered genes related to cell movement in the microarray (Student’s t test, p value is
***p < 0.001). Three lungs of WT mice and three lung tumors of Ptend/dSmad4d/d mice were analyzed.
(D) Alignment of the gene signature of our Ptend/dSmad4d/d mouse tumors with the Takeuchi lung cancer database (GSE11969). A score greater than zero
represents a positive correlation with the murine gene signature. This data set encompasses expression profiles in 149 patients with NSCLC, nine patients with
SCLC, and five patients with normal lung tissue. AD (n = 90, adenocarcinoma), AS (n = 4, adenosquamous carcinoma, LA (n = 18, large-cell carcinoma), and
LCNEC (n = 2, large-cell neuroendocrine carcinoma). SCLC (n = 9, small cell lung cancer), SCC (n = 35, squamous cell lung cancer), and normal lung tissue (n = 5).
Boxplot represents 5%, 25%, 75%, median, and 95%.analysis was performed with RNA samples from the lung tissues
of Ptend/d mice and Ptend/dSmad4d/d mice at the age of
7 months. At this age, mice had hyperplasia but no cancer so
that this stage was considered to be the early/initiating stage
of lung cancer in our mouse models. 744 genes were found to
be significantly altered in lung tissues of Ptend/dSmad4d/d mice
in comparison with those of Ptend/d mice, which reflected the
early molecular signature of the tumors exerted by Smad4. We
validated the expression of a representative of altered genes
discovered in the array (Figures S4A and S4B).1604 Cell Reports 10, 1599–1613, March 10, 2015 ª2015 The AuthorGiven that SMAD4 is a transcriptional factor (Massague´ et al.,
2005), we employed SMAD4 chromatin immunoprecipitation
(ChIP) followed by high-throughput DNA sequencing (ChIP-
seq) on whole-lung tissue from 7-month-old Ptend/d mice to
identify genes that were directly bound by SMAD4. The
SMAD4 binding sites were highly enriched in the proximal pro-
moter regions of 13,103 genes (Table S4) as compared to the
reference genome locus (Figures S4C and S4D). We identified
235 potential direct gene targets of SMAD4 by comparing genes
with altered expression in microarray data (Ptend/dSmad4d/ds
Figure 4. Deletion of Smad4 in Pten-Null Background Activates the ErbB2/Akt Signaling
(A) Top changed upstream regulators identified by IPA of the intersection genes between gene microarray data set and SMAD4 ChIP-seq data set.
(B and C) WB (B) and IHC (C) analyses of protein expression and phosphorylation of the ERBB2/AKT signaling pathway in 7-month-old mouse lungs. p-ERBB2,
ERBB2 phosphorylation. p-AKT, AKT phosphorylation. Number below each protein band indicates the relative band intensity (signal) measured by ImageJ
software (NIH).
(D and E) IHC (D) and WB analyses (E) of protein expression and phosphorylation of ERBB2/AKT signaling pathway in 12-month-old mouse lungs and lung
tumors. Number below each protein band indicates the relative band intensity (signal) measured by ImageJ software (NIH).
(F) Kaplan-Meier plot of survival probability based on the ERBB2 mRNA expression index in squamous cell lung carcinoma patients from TCGA data set. The
mean expression value of ERBB2 across all investigated patients was calculated. Patients with ERBB2 expression higher than mean ERBB2 expression were
classified into the ERBB2 high group, while patients with ERBB2 expression lower than mean ERBB2 expression were classified into the ERBB2 low group.versus Ptend/d) and genes identified in SMAD4 ChIP-seq data
sets. Utilizing IPA, we found that ERBB2 regulated 24 of the
235 direct gene targets ranking top among upstream regulators
(Figure 4A). Consistently, both ERBB2 protein expression
and phosphorylation were increased in the lung epithelium of
7-month Ptend/dSmad4d/d mice, as compared to those of WT,
Smad4d/d, and Ptend/d mice. As expected, phosphorylation of
AKT (p-AKT) was increased in Ptend/d mice. Intriguingly, p-AKT
was further increased upon deletion of Smad4 (Ptend/dSmad4d/d
versus Ptend/d) (Figures 4B and 4C), suggesting SMAD4 may
prevent the full activation of AKT upon the deletion of Pten. Up-
regulation of ErbB2/Akt signaling remained in the lung tumorsCellof Ptend/dSmad4d/d mice at 12 months of age, as demonstrated
by the increase of ERBB2 expression and ERBB2 and Akt phos-
phorylations (Figures 4D and 4E), suggesting a continuous acti-
vation of the ErbB2/Akt pathway in the process of Ptend/d
Smad4d/d mouse tumor development. Similar to ERBB2, other
members of the ERBB family, including EGFR, ERBB3, and
ERBB4, also had increased phosphorylation (albeit at variable
levels) upon the deletion of Pten and Smad4, especially in the
lung tumors (Figure S4E). In contrast with the continuous hyper-
activation of Akt, both MAPK and mTOR phosphorylations were
only modestly altered in Ptend/dSmad4d/d mice, as compared to
WT, Smad4d/d, or Ptend/d mice (Figure S4F).Reports 10, 1599–1613, March 10, 2015 ª2015 The Authors 1605
In order to investigate whether there was a similar phenotype
in human cells, knockdown of PTEN and SMAD4 in BEAS-2B
cells was performed and increased both ErbB2 and Akt phos-
phorylations were observed, confirming a cooperative regulatory
function of PTEN and SMAD4 in human lung epithelial cells (Fig-
ure S4G). We next evaluated the clinical relevance of increased
ERBB2 signaling using the lung cancer TGCA data sets. Consis-
tent with our in vivo and in vitro studies, dividing lung SCC pa-
tients into two groups based on the expression of ERBB2, we
found that higher expression of ERBB2 was associated with
poor patient survival in lung SCC patients in the TCGA data set
(Figure 4F). Together, these findings suggest that ErbB2
signaling plays an important role in Ptend/dSmad4d/d lung tumors
and human lung cancers.
Blockade of ErbB2/Akt Signaling Pathway Inhibits
Tumor Growth Induced by Pten/Smad4 Deficiency
Given the important oncogenic role of ErbB2/Akt signaling
pathway in human cancers and its activation in Ptend/dSmad4d/d
lung tumors, we investigated its role in enhanced cell growth and
invasion. We used specific inhibitors that targeted the essential
molecules within the ErbB2/Akt signaling pathways: GDC-
0941, the specific inhibitor of PI3K; Herceptin, a mono-antibody
against ERBB2; and Lapatinib, the dual kinase inhibitor of ERBB2
and EGFR (Folkes et al., 2008; Langer et al., 2004; Gril et al.,
2008). While treatment with these inhibitors had no significant ef-
fect on invasion of BEAS-2B cells transfected with control
siRNAs (siControl), single or combinatorial treatment with these
inhibitors greatly inhibited the increase of cell invasion induced
by the double knockdown of PTEN and SMAD4 (Figures 5A
and 5B). Next, we tested the importance of ErbB2/Akt signaling
in tumor progression of Ptend/dSmad4d/d mice. Given the combi-
natorial inhibitory effect of Lapatinib and GDC-0941 on cell inva-
sion, we treatedPtend/dSmad4d/d mice (9-month-old) for 30 days
using oral gavage. As compared to vehicle (DMSO) control, the
combinatorial treatment with Lapatinib and GDC-0941 signifi-
cantly inhibited phosphorylations of ERBB2 and AKT (Figure S5)
and lung tumor growth and progression, as demonstrated by the
significant decrease in the weight ratio of whole lung to whole
body, the number of mice with surface tumors, the average num-
ber of surface tumors, and the size (diameter) of maximal surface
tumors (Figures 5C–5G).
Errfi1, a Negative Regulator of ErbB2 Signaling, Plays
Critical Roles in Tumor Progression in the Pten-Null
Background
Having defined the critical role of ErbB2 signaling in promoting
tumor growth and progression in Ptend/dSmad4d/d mice, we
determined the cause of the increase in ERBB2 phosphorylation
(activity) in these mice. Combinatorial intersection analysis of our
microarray data and SMAD4 ChIP-seq data revealed that Errfi1
(ERBB receptor feedback inhibitor 1), a known negative regulator
of ERBB signaling (Hackel et al., 2001; Zhang et al., 2012; Zhang
et al., 2007), was significantly downregulated in Ptend/dSmad4d/d
lung tumors (Figure S6A) and was a potential target of SMAD4 in
Ptend/dmice (Figures S6B andS6C). The downregulation of Errfi1
expression in Ptend/dSmad4d/d lungs was verified at both the
mRNA level (Figure 6A) and the protein level (Figure 6B). As1606 Cell Reports 10, 1599–1613, March 10, 2015 ª2015 The AuthorERRFI1 was shown to inhibit ErbB2 signaling in thyroid and
breast cancer (Lin et al., 2011; Anastasi et al., 2005) and to act
as a tumor suppressor in lung cancer (Zhang et al., 2007; Tseng
et al., 2005), our results suggested that downregulation of Errfi1
might contribute to increased ERBB2 phosphorylation and lung
tumor growth and metastasis in mouse models. To investigate
the role of Errfi1 in lung tumorigenesis, using the CCSPiCre, Errfi1
was conditionally ablated alone, Errfi1d/d, or in combination with
Pten. Deletion of Errfi1 led to a great increase of ERBB2 phos-
phorylation in mouse lung upper airways (Figures 6C and 6D).
While only 1 in 15 Errfi1d/d mice had lung tumor growth at
9 months of age, 71% of Errfi1d/dPtend/d mice formed lung tu-
mors at the same age (Figures 6E and 6F). Interestingly, a similar
tumor incidence was observed for Errfi1d/dPtend/d mice (71.4%)
and Ptend/dSmad4d/d mice (67%). Markers staining indicated tu-
mors from Errfi1d/dPtend/d mice belonged to AD (Figures S6D–
S6F). Taken together, these results suggest that Errfi1 acts as a
suppressor of ErbB2 signaling and prevents lung tumor growth
in the Pten-null background; downregulation of Errfi1 upon the
deletion of Smad4 in Ptend/dSmad4d/d mice led to increased
ErbB2 signaling and lung tumorigenesis.
ELF3 Is a Novel Target Gene in the ErbB2 Pathway
Directly Regulated by SMAD4 in PTEN-Null or -Low
Background
Given our findings on the essential role of activated ErbB2/Akt
signaling in promoting Ptend/dSmad4d/d lung tumors, we next
explored downstream target(s) of this pathway that may play a
significant role in tumor progression. Analyzing the genes that
showed a consistent change in the early- and late-stage lung tu-
mors, we found ELF3, a transcriptional factor known to have
oncogenic activity in breast cancer (Coppe et al., 2010), ranked
on the top position in genes regulated by ErbB2 signaling (Fig-
ure S7A). Mining the SMAD4 ChIP-seq analysis demonstrated
SMAD4 bound the proximal promoter region the ELF3 gene (Fig-
ure S7B), which was validated by ChIP-qPCR (Figure 7A). The
upregulation of Elf3 was validated at both mRNA (Figure 7B)
and protein levels (Figures 7C and 7D) in the lungs of 7-month-
old Ptend/dSmad4d/d mice and in lung tumors isolated from
12-month-old Ptend/dSmad4d/d mice (Figure S7C). Interestingly,
Elf3was also found to be significantly upregulated in the lungs of
Ptend/d mice, albeit at a lesser level than that of Ptend/dSmad4d/d
mice, suggesting that Elf3 is regulated by both PTEN and
SMAD4 tumor suppressors. Consistent with this in vivo finding,
knockdown ofPTEN andSMAD4 increased ELF3mRNA expres-
sion in BEAS-2B cells (Figure 7E). In addition, ELF3was downre-
gulated by TGF-b1, an upstream stimulus of SMAD4, and deple-
tion of SMAD4 abolished this inhibitory effect (Figure 7F). These
results demonstrated that ELF3 was a gene directly and nega-
tively regulated by SMAD4. We then determined the importance
of ELF3 on cell proliferation and invasion. Knockdown of ELF3
significantly decreased both proliferation and invasion of
BEAS-2B cells, most prominently in the context of both PTEN
and SMAD4 double deletion (Figures 7G–7I). Analysis of Onco-
mine data sets revealed that ELF3 was highly upregulated in
lung cancer (Figures S7E and S7F), and its upregulation is posi-
tively associated with poor survival and with early recurrence
(Figures S7G and S7H).s
Figure 5. Blockade of ErbB2/Akt Signaling Pathway Inhibits Tumor Growth Induced by Pten/Smad4 Deficiency
(A) Two chamber invasion assays of Beas-2B cells with knockdown of PTEN and SMAD4 (siSMAD4/PTEN) and the treatment of kinase inhibitors as indicated.
(B) Quantification of the results (A) using one-way ANOVA (p value is *p < 0.05, **p < 0.01, ***p < 0.01).
(C–G) Inhibition of tumor formation in 9-month-old Ptend/dSmad4d/d mice the treatment of kinase inhibitors. Representative whole-lung images and H&E staining
of lung tissues in WT and Ptend/dSmad4d/d mice are shown in (C). Quantitative analysis of tumor growth in Ptend/dSmad4d/d mice with or without the treatment of
kinase inhibitors is shown in (D)–(G). Statistical analysis was performed using one-way ANOVA (p value is *p < 0.05, **p < 0.01, ***p < 0.01) on the ratio of whole
lung to whole body and using Student’s t test (p value is **p < 0.01) on themaximal diameter and the number of surface tumors. Black arrows indicate lung tumors.These results highlight the clinical relevance of the Ptend/d
Smad4d/d lung tumor model: Pten deletion in airway epithelial
cells induces airway epithelia cell hyperplasia probably second-Cellary to the compensatory activation of SMAD4. Further depletion
of Smad4 in Ptend/d mice results in activation of ErbB2, probably
through the downregulation of ERRFI1, and further activates AktReports 10, 1599–1613, March 10, 2015 ª2015 The Authors 1607
Figure 6. Errfi1, a Negative Regulator of ErbB2 Signaling, Plays Critical Roles in Tumor Progression in the Pten-Null Background
(A and B) Quantitative real-time PCR (A) and WB (B) analyses of Errfi1 expression level in mouse lungs and lung tumors.
(C and D) WB (C) and IHC (D) analyses of p-ERBB2/ERBB2 and p-AKT/AKT signaling in 9-month-old mouse lungs.
(E and F) Primary lung tumors were observed in the Errfi1d/dPtend/d mouse lungs. (E) The primary lung tumors are indicated by black arrows. (F) Summary of
Errfi1d/dPtend/d mice with frequency of lung tumor.
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Figure 7. ELF3 Is a Novel Target Gene of the ErbB2 Pathway and Is Directly Regulated by SMAD4 in PTEN-Null or -Low Background
(A) ChIP-qPCR analysis of SMAD4 binding on the Elf3 promoter region in 7-month-old Ptend/d mouse lungs. The primers for Untra 10 are targeted on the
untranslated region 10.
(B–D) Quantitative real-time PCR (B), WB (C), and IHC (D) analyses of Elf3 expression in 7-month-old mouse lungs.
(E) Quantitative real-time PCR analysis of ELF3 mRNA expression in BEAS-2B cells after knockdown of PTEN and/or SMAD4.
(F) Quantitative real-time PCR analysis of the ELF3 mRNA expression in BEAS-2B cells with the knockdown of PTEN and SMAD4 and with or without the
treatment of TGF-b1. Statistical analysis was performed using one-way ANOVA (p value is *p < 0.05, **p < 0.01, and ***p < 0.001).
(G) MTT assay of cell viability in Beas-2B cells after the knockdown of PTEN, SMAD4, and ELF3. Statistical analysis was performed using Student’s t test (p value
is **p < 0.01).
(H and I) Two-chamber invasion assay of Beas-2B cells after knockdown of PTEN, SMAD4, and/or Elf3. Representative images of cell invasion are shown in (H),
and quantitation of cell invasion is shown in (I). Statistical analysis was performed using Student’s t test (p value is *p < 0.05, **p < 0.01, ***p < 0.01).
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signaling pathway and induces expression of ERBB2 target
genes including Elf3, which promoted lung tumor growth and
progression.
DISCUSSION
In this report, we have developed a newmouse model to identify
critical molecules and signaling pathways that play key roles in
driving tumor initiation and progression in hyperplastic (e.g.,
Pten-null) airway epithelial cells. Pten loss has been shown to
be highly relevant in lung cancer development (Malkoski et al.,
2014; Xu et al., 2014). However, initial investigations using the
CCSPCre model to delete the Pten gene in mouse airway epithe-
lial cells showed no discernible phenotype (Iwanaga et al., 2008).
Here, we found that Pten ablation using the improved CCSPicre
showed consistent airway epithelial hyperplasia without any pro-
gression to cancer (up to 15 months); these findings are in
contrast to the reports that AD develop in the lungs of mice
with SP-Ccre-mediated deletion of Pten (Yanagi et al., 2007).
Further, a mixed ADC and SCC phenotype has been reported
in the mice lacking Pten in the airway basal cells (Malkoski
et al., 2014). These findings provide a cell-specific and geo-
graphically distinct mechanism of tumor suppressor activation
for Pten and support the hypothesis that progression of hyper-
plastic epithelial cells in the proximal airways requires additional
alterations in tumor suppressor genes and/or signaling path-
ways. In support of this hypothesis, we discovered the activated
tumor suppressor TGF-b/SMAD4 signaling pathway in Ptend/d
mice, a plausible mechanism protecting the hyperplastic airway
epithelial cells to lung tumors. In support of our findings, a pro-
tective role for SMAD4 has been described in other epithelial
derived tumors, such as prostate cancer (Ding et al., 2011); our
findings demonstrate for the first time that concurrent loss of
Pten and Smad4 induces tumor growth and metastasis in lung
cancer and shows how similar cancer driver genes behave in
epithelial tumors. Further, our novel lung tumor model also
shares similar characteristics with human SCC lung cancer,
including their initiation site in the proximal airways and lack
type II alveolar airway phenotypic markers (Figures 2B–2D) (Su-
therland and Berns, 2010). Additionally, much like human lung
cancers, Ptend/dSmad4d/d lung tumors spontaneously metasta-
size to other organs, including the liver and stomach; albeit, in
humans, metastasis to the gastric mucosa had been reported
at low frequency (Figures 2F and 2G) (Lee et al., 2011). In support
of the relevance of the Ptend/dSmad4d/d lung cancer model, we
show that the gene signature identified in this tumor model is
highly consistent with that of human lung cancers (Figure 3D).
In our current study, we identified the activation of the ErbB2
pathwaywith concurrent loss ofPten andSmad4 prior to primary
tumor formation. The hyperactivation of ErbB2 signaling is in par-
allel with remarkable reduction of Errfi1, a known inhibitor of
ERBB2 activity, suggesting a molecular mechanism for the acti-
vation of ErbB2 signaling upon the loss of both Pten and Smad4.
In support of this, concurrent loss of Errfi1 and Pten in lungs also
led to upregulation of ERBB2 signaling and high tumor inci-
dence. This important finding not only provides a mechanism
for SMAD4-mediated suppression of lung tumor in hyperplastic
airway epithelia cells inPten-null mice, but also suggests that the1610 Cell Reports 10, 1599–1613, March 10, 2015 ª2015 The AuthorErbB2 signaling pathway could be used as a diagnostic bio-
marker and targeted to prevent lung tumor progression. Indeed,
the ErbB2 signaling pathway is highly upregulated in human lung
cancer (Minami et al., 2007; Stephens et al., 2004; Arcila et al.,
2012; Greulich et al., 2012; Mazie`res et al., 2013), and ERBB2
has been recently found to be one of the driver genes in human
lung AD (Cancer Genome Atlas Research Network, 2014). More
importantly, we show that inhibition of the ErbB2 signaling
pathway by combinatorial treatment with Herceptin and GDC-
0941 inhibited cell invasion and tumor progression.
We have also identified ELF3 as a novel direct inhibitory target
of SMAD4 that plays an important role in lung cancer, and ELF3
showed significant positive correlation with ERBB2 in human
lung adenocarcinoma, indicating that it may be a very important
downstream gene in ErbB2 signaling in lung cancer (Figure S7K).
To our knowledge, our study is the first to demonstrate that Elf3
is highly upregulated upon deletion of Smad4 and plays an
important role in lung cell proliferation and invasion. Interestingly,
ELF3 was shown to be an upstream regulator of SPP1 (Coppe
et al., 2010), which was identified as a key gene regulated by
PTEN and SMAD4 in a murine model of metastatic prostate can-
cer (Ding et al., 2011). Although the overlap in altered genes
observed in the prostate cancer tumors was minimal when
compared to the lung Ptend/dSmad4d/d mouse model (data not
shown), we found high expression of SPP1 and Elf3 in Ptend/d
Smad4d/d lung tumors (Figures S7C and S7L ), indicating that
ELF3might play the conserved role to drive cancer development
andmetastasis. In addition, we show that ELF3 is overexpressed
in human lung cancer (Figures S7E and S7F) and its upregulation
in human lung cancer cells with PI3KCA and SMAD4 mutations
(Figures S7I and S7J). All the evidence indicates that ELF3 could
be new potential target for lung cancer treatment.
Although the tumor types between Ptend/dSmad4d/d and
Errfi1d/dPtend/d mouse models were different, both of them
showed activated ERBB2 and AKT signaling. This indicated
that other genes regulated by SMAD4 are required to work coop-
eratively with ERBB2/Akt signaling for the development of lung
SCC in Ptend/dSmad4d/d mice. Comparing our Ptend/dSmad4d/d
tumor gene array with the pure lung SCC mouse tumor array
(Ad-Cre-Ptenf/fLkb1f/f) and the pure AD mouse tumor array (Ad-
Cre-KrasG12D) (Xu et al., 2014), we found 341 genes only overlap-
ping between the Ptend/dSmad4d/d tumor array and the Ad-Cre-
Ptenf/fLkb1f/f mouse array (Figure S3), including the marker
genes for SCC, such as p63, Sox2, and Krt5 (Table S5). Impor-
tantly, p63 and Sox2 have recently been proved to regulate the
development of SCC in mice (Han et al., 2014; Mukhopadhyay
et al., 2014). Consistent with the AD tumor type observed in
Errfi1d/dPtend/dmousemodels, p63, SOX2, and KRT5 are not ex-
pressed in these tumors (Figure S6D).
In summary, we successfully generated a metastatic lung tu-
mor model with airway-specific deletion of Pten and Smad4
and showed that their sequential alterations induce oncogenic
pathways including ErbB2/Akt/ELF3 and represses tumor sup-
pressors, such as Errfi1, that are critical for lung tumor initiation
and progression. Given the long latency of tumor progression in
this model, it can be used to determine what other factors
are critical for promoting tumor progression and metastasis.
These studies include determining the impact of environmentals
exposures to airborne carcinogens aswell as functional genomic
screening for modifiers of tumor progression and metastasis in
this model. Since the in vivo analysis in this mouse model can
be recapitulated in human airway cells in vitro, further mecha-
nistic studies can be conducted. These studies will be able to
define the mechanism by which altering the expression of
PTEN causes the increase in TGF-b signaling. Cistromic analysis
in human cells will identify the genes directly regulated by
SMAD4 in preventing tumor progression. These approaches
will also identify other pathways that are ideal for treating lung
cancer at early stages and for preventing cancer progression.
EXPERIMENTAL PROCEDURES
Generation of Ptend/d, Smad4d/d, Ptend/d Smad4d/d, Errfi1d/d, and
Errfi1d/dPtend/d Mice
All animal experiments were performed in accordance with an IACUC
approved protocol (Baylor College of Medicine, Houston, TX). Details are in
the Supplemental Information.
Histopathology, Immunohistochemistry, Immunofluorescence, and
Western Blotting
Mouse lungs were fixed in 4% paraformaldehyde and paraffin embedded ac-
cording to standard protocols. Details are in the Supplemental Information.
Cell Derivation and Culture
Beas-2B (ATCC CRL-9609) and NL20 (ATCC CRL-2503) cells were purchased
from ATCC and cultured by following the ATCC culture condition. 293T cells
were purchased from Tissue Culture Core in Baylor College of Medicine. De-
tails are in the Supplemental Information.
Senescence Experiment
Frozen lung sections were prepared from 10-month-oldmice, and the standard
protocol of Senescence Detection Kit (Abcam, cat. Ab65351) was utilized.
Microarray, Quantitative Real-Time PCR
Total RNAs were isolated from mouse lungs with TRIzol reagent (Invitrogen)
and reversely transcribed into cDNA with a M-MLV kit (Invitrogen). The
mRNA expression levels of human and mouse were determined by quantita-
tive real-time PCR by using SYBR Green and TaqMan probes (Applied
Biosystems). Statistical analysis was performed using one-way ANOVA and
Student’s t test (p value is *p < 0.05, **p < 0.01, and ***p < 0.001).
Mouse Lung Cancer Microarray
Details are in the Supplemental Information.
Human Lung Cancer Samples and Tissue Microarray
All human lung tissues were obtained from the Lung Cancer Specialized Pro-
gram of Research Excellence (SPORE) Tissue Bank at the MD Anderson Can-
cer Center and an IRB was approved for expression studies from this Tissue
Bank. Details are in the Supplemental Information.
siRNA and Small Hairpin RNA Experiments
For siRNA experiments, ON-TARGET plus siRNAs SMARTpools (Thermo)
were used. For small hairpin RNA (shRNA) experiments, all the pGIPZ lentivirus
shRNA plasmids were purchased from the C-BASS Core at Baylor College of
Medicine. Details are in the Supplemental Information.
CHIP-Seq and Chip-qPCR
Details are in the Supplemental Information.
Transwell Migration Assay, Invasion Assay, and MTS Assay
Standard 24-well Boyden control and invasion chambers (BD Biosciences)
were used to assess cell migration and invasion following manufacturer sug-
gestions. Details are in the Supplemental Information.CellInhibitors Treatment
Inhibitors GDC-0941(LC Laboratories, G-9252), Lapatinib (LC Laboratories,
L-4899), and Herceptin (BOC Sciences, 180288-69-1) were dissolved in
DMSO. DMSO was used as the control. Details are in the Supplemental
Information.
Human Lung Tumor Expression Data Sets
The gene expression array data set GSE11969 (Takeuchi et al., 2006) was
probed using themouse lung cancer gene signature, usingpreviously described
approaches (Qin et al., 2013). Data sets in Oncomine (https://www.oncomine.
org) were also examined. RNA sequencing data of Lung Squamous Cell
Carcinoma (LUSC) and Lung Adenocarcinoma (LUAD) were obtained through
TCGA pan-cancer synapse (https://www.synapse.org/#!Synapse:syn300013).
Details are provided in Supplemental Experimental Procedures.
ACCESSION NUMBERS
The GEO accession number for the microarray data reported in this paper is
GSE57133. The GEO accession number for the ChIP-seq data reported in
this paper is GSE57177.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and seven tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2015.02.014.
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